AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25059701 — intervention group
Group type: COMPARATOR
Intervention: CT table strap placed around the torso and arms (control group)
Number of subjects: 51
Study 22251436 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg BID for 12 weeks
Number of subjects: 110
Study 22251436 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 110
Study 20138472 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial electromechanical conduction time (EMT) measured by echocardiography
Number of subjects: 53
Study 20138472 — intervention group
Group type: COMPARATOR
Intervention: Control group with sinus rhythm (SR)
Number of subjects: 53
Study 17082513 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin/paclitaxel
Number of subjects: 103
Study 17082513 — intervention group
Group type: EXPERIMENTAL
Intervention: carboplatin/paclitaxel
Number of subjects: 103
Study 15727644 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (one pass)
Number of subjects: 22
Study 15727644 — intervention group
Group type: COMPARATOR
Intervention: Q-switched Nd:YAG laser (three treatment sessions)
Number of subjects: 22
Study 11885833 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor-held card
Number of subjects: 1275
Study 11885833 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-held card
Number of subjects: 1275
Study 11885833 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1275
Study 9790083 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal liver assist device (ELAD) hemoperfusion
Number of subjects: 12
Study 9790083 — intervention group
Group type: COMPARATOR
Intervention: Control group (intensive care alone)
Number of subjects: 12
Study 9097772 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral computed tomography (CT)
Number of subjects: 34
Study 2692763 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 20
Study 2692763 — intervention group
Group type: COMPARATOR
Intervention: Trazodone
Number of subjects: 20
Study 141860 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐Br‐ergocriptine (bromocriptine, CB‐154)
Number of subjects: 12
Study 141860 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study 29347825 — intervention group
Group type: EXPERIMENTAL
Intervention: FatherWorks intervention (15 session parenting intervention, 13 session employment class, paid internship, case management, and access to behavioral health services)
Number of subjects: 328
Study 29347825 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (24/7 Dads)
Number of subjects: 328
Study 30378221 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP with 15 cmH2 O
Number of subjects: 10
Study 30378221 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP with 4 cmH2 O
Number of subjects: 10
Study 30378221 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP with 0 cmH2 O
Number of subjects: 10
Study 30378221 — intervention group
Group type: EXPERIMENTAL
Intervention: All levels of CPAP (0, 4, and 15 cmH2 O)
Number of subjects: 10
Study 28556766 — intervention group
Group type: EXPERIMENTAL
Intervention: B-Active2 (Enjoy Being Physically Active by Walking Safely: A Leisure Education Program)
Number of subjects: 44
Study 25494719 — intervention group
Group type: EXPERIMENTAL
Intervention: STOMA psychosocial intervention
Number of subjects: 84
Study 25494719 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 84
Study 23597853 — intervention group
Group type: EXPERIMENTAL
Intervention: Interictal epileptiform discharges (IEDs)
Number of subjects: 0
Study 23597853 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic epileptic discharges/subtle status epilepticus (PEDs/subtle SE)
Number of subjects: 0
Study 23597853 — intervention group
Group type: COMPARATOR
Intervention: Rhythmic fast activities background (RFAB) pattern
Number of subjects: 0
Study 22011889 — intervention group
Group type: EXPERIMENTAL
Intervention: C&B Cement (CB)
Number of subjects: 20
Study 22011889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac Cem (KC)
Number of subjects: 20
Study 22011889 — intervention group
Group type: EXPERIMENTAL
Intervention: GC FujiCEM (FC)
Number of subjects: 20
Study 22011889 — intervention group
Group type: EXPERIMENTAL
Intervention: Water storage (T7 and T90)
Number of subjects: 20
Study 22011889 — intervention group
Group type: COMPARATOR
Intervention: Control group (no water storage)
Number of subjects: 20
Study 19105432 — intervention group
Group type: EXPERIMENTAL
Intervention: Yishen Zhuanggu decoction (YSZGD), orally, one potion two times each day
Number of subjects: 90
Study 19105432 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (50 units, intramuscular, 2 times each week), Caltrate D (1 tablet, orally, once daily), Alfacalcidol Soft Capsules (0.5 units, orally, once daily)
Number of subjects: 90
Study 19105432 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medicine)
Number of subjects: 90
Study 19105432 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM group (YSZGD)
Number of subjects: 90
Study 19105432 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine group
Number of subjects: 90
Study 16497637 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutrition and lifestyle counselling (at least twice a year)
Number of subjects: 1062
Study 16497637 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1062
Study 12910512 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy (MT)
Number of subjects: 237
Study 12910512 — intervention group
Group type: COMPARATOR
Intervention: Breast conservation therapy (BCT)
Number of subjects: 237
Study 10321561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a standardized Dermatophagoides pteronyssinus (DP)‐D. farinae (DF) 50/50 extract, cumulative dose of about 104000 IR over 24 months.
Number of subjects: 85
Study 10321561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 85
Study 10321561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 10321561 — intervention group
Group type: COMPARATOR
Intervention: Both groups (SLIT and placebo)
Number of subjects: 85
Study 8561338 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tropisetron
Number of subjects: 80
Study 8561338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 1658863 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol treatment
Number of subjects: 187
Study 1658863 — intervention group
Group type: COMPARATOR
Intervention: No anti-edema treatment
Number of subjects: 187
Study 6764750 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine
Number of subjects: 50
Study 6764750 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 6764750 — intervention group
Group type: EXPERIMENTAL
Intervention: observation cycle
Number of subjects: 50
Study 6764750 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 month follow-up
Number of subjects: 50
Study 30928882 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive political rhetoric
Number of subjects: 280
Study 30928882 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative political rhetoric
Number of subjects: 280
Study 30928882 — intervention group
Group type: COMPARATOR
Intervention: Neutral rhetoric
Number of subjects: 280
Study 28481007 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib plus rabeprazole
Number of subjects: 55
Study 28481007 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib plus placebo
Number of subjects: 55
Study 24495461 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA
Number of subjects: 25
Study 24495461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 22865728 — intervention group
Group type: EXPERIMENTAL
Intervention: Hadad‐Bassagasteguy (HB) flap reconstruction
Number of subjects: 20
Study 22865728 — intervention group
Group type: COMPARATOR
Intervention: Synthetic or nonautologous materials for reconstruction
Number of subjects: 20
Study 21625426 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (10 µg/kg body weight/day for 10 days)
Number of subjects: 41
Study 21625426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 18346960 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy
Number of subjects: 2865
Study 16413442 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Growth Factors (AGF) combined with allograft
Number of subjects: 37
Study 16413442 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest bone graft (autograft)
Number of subjects: 37
Study 12789899 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10846898 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict control of food and fluid intake
Number of subjects: 0
Study 9487771 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal plaster (NP, Breathe‐Right)
Number of subjects: 50
Study 7933440 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous enteral feeding
Number of subjects: 12
Study 7933440 — intervention group
Group type: COMPARATOR
Intervention: Discontinuous enteral feeding
Number of subjects: 12
Study 3064972 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release diazepam (10 mg once daily)
Number of subjects: 114
Study 3064972 — intervention group
Group type: COMPARATOR
Intervention: Conventional diazepam (5 mg 3-times daily)
Number of subjects: 114
Study 29891606 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g every day (QD) for 7 doses
Number of subjects: 18
Study 29891606 — intervention group
Group type: COMPARATOR
Intervention: 3 g every other day (QOD) for 3 doses
Number of subjects: 18
Study 26936043 — intervention group
Group type: EXPERIMENTAL
Intervention: New drug trials
Number of subjects: 0
Study 25913417 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia
Number of subjects: 0
Study 25913417 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 0
Study 25913417 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 23733372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg
Number of subjects: 45
Study 23733372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 900 μg
Number of subjects: 45
Study 23733372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 1200 μg
Number of subjects: 45
Study 23733372 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 45
Study 20647285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive individualised dietary advice for six months
Number of subjects: 93
Study 18753810 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye protective device
Number of subjects: 75
Study 18753810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear protective device
Number of subjects: 75
Study 18753810 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye protective device and ear protective device
Number of subjects: 75
Study 18753810 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 16603776 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Number of subjects: 338
Study 16603776 — intervention group
Group type: COMPARATOR
Intervention: plain lubricant gel
Number of subjects: 338
Study 11861728 — intervention group
Group type: EXPERIMENTAL
Intervention: Open carpal tunnel release with flexor tenosynovectomy
Number of subjects: 87
Study 11861728 — intervention group
Group type: COMPARATOR
Intervention: Open carpal tunnel release without flexor tenosynovectomy (control)
Number of subjects: 87
Study 9702620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 5 mg i.v. rapid infusion
Number of subjects: 36
Study 9702620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 10 to 15 mg i.v. rapid infusion
Number of subjects: 36
Study 9702620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 1.25 to 5 mg i.v. bolus
Number of subjects: 36
Study 9702620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 5 mg i.v. bolus
Number of subjects: 36
Study 9702620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 2.5 to 5 mg i.v. bolus with labetalol 10 mg i.v.
Number of subjects: 36
Study 9702620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine as part of anesthetic regimen for ECT
Number of subjects: 36
Study 9702620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 2.5 mg i.v. bolus with labetalol 10 mg i.v.
Number of subjects: 36
Study 7891260 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking (NNS)
Number of subjects: 20
Study 7891260 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 20
Study 2239218 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate for 4 weeks
Number of subjects: 264
Study 2239218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 344110 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 0
Study 344110 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 7045314 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral high-dose prednisone therapy (2 mg/kg/day)
Number of subjects: 22
Study 7045314 — intervention group
Group type: COMPARATOR
Intervention: Pulse methylprednisolone therapy (30 mg/kg/day, not to exceed 1 gm/day) followed by prednisone (2 mg/kg/day)
Number of subjects: 22
Study 30418101 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth self-monitoring (TSM)
Number of subjects: 104
Study 30418101 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive outpatient management (COM)
Number of subjects: 104
Study 29573355 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma levels of neopterin
Number of subjects: 8913
Study 29573355 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopterin and CRP levels above the median
Number of subjects: 8913
Study 26615503 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocryl® Plus suture
Number of subjects: 20
Study 26615503 — intervention group
Group type: COMPARATOR
Intervention: Silk suture
Number of subjects: 20
Study 24890542 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel 60-mg loading dose (n = 25)
Number of subjects: 50
Study 24890542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 360-mg loading dose (n = 25)
Number of subjects: 50
Study 22865589 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative topical antimicrobial decolonization with a 5-day regimen of chlorhexidine skin rinses and intranasal mupirocin coupled with standard perioperative systemic antimicrobial prophylaxis
Number of subjects: 84
Study 22865589 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylaxis alone
Number of subjects: 84
Study 18952203 — intervention group
Group type: COMPARATOR
Intervention: Stilt height of 0'' (no stilts)
Number of subjects: 20
Study 18952203 — intervention group
Group type: EXPERIMENTAL
Intervention: Stilt height of 24''
Number of subjects: 20
Study 18952203 — intervention group
Group type: EXPERIMENTAL
Intervention: Stilt height of 40''
Number of subjects: 20
Study 18952203 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot placement with one foot forward
Number of subjects: 20
Study 18952203 — intervention group
Group type: EXPERIMENTAL
Intervention: Feet parallel and directly beneath the body
Number of subjects: 20
Study 18952203 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot placement with feet positioned a half shoulder width apart
Number of subjects: 20
Study 17486917 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 17486917 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 40
Study 15531906 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (12 mg single dose)
Number of subjects: 24
Study 15531906 — intervention group
Group type: COMPARATOR
Intervention: Unconjugated G-CSF (8.5 mug/kg/day)
Number of subjects: 24
Study 15531906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions post high-dose melphalan (200 mg/m2) and autografting
Number of subjects: 24
Study 11983189 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion SR 300 mg/day
Number of subjects: 423
Study 11983189 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 423
Study 10990148 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (6.7 microg/kg/day for 12 weeks)
Number of subjects: 20
Study 10990148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7608429 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (200 mg/day)
Number of subjects: 219
Study 7608429 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus regular heparin (400 IU/kg body weight per day intravenously)
Number of subjects: 219
Study 7608429 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus low molecular weight heparin (214 UIC/kg anti‐Xa twice daily subcutaneously)
Number of subjects: 219
Study 2109613 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modifying antirheumatic drugs (DMARDs)
Number of subjects: 130
Study 2109613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 606780 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-virus vaccines (400 CCA units/0.5 ml or 200 CCA units/0.25 ml)
Number of subjects: 185
Study 606780 — intervention group
Group type: EXPERIMENTAL
Intervention: Ether-extracted, subunit vaccines (with or without 1.5 mg of A1PO4/0.5 ml)
Number of subjects: 185
Study 606780 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of ether-extracted, subunit virus vaccine with Hsw1N1 antigen
Number of subjects: 185
Study 606780 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosage regimen of two doses administered at least four weeks apart
Number of subjects: 185
Study 30192341 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical extra virgin olive oil for massaging
Number of subjects: 60
Study 30192341 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam gel
Number of subjects: 60
Study 30192341 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin oil
Number of subjects: 60
Study 30192341 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry massaging
Number of subjects: 60
Study 30192341 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine drugs alone
Number of subjects: 60
Study 30651573 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs6684439 in IL6R
Number of subjects: 559
Study 30651573 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs4845622 in IL6R
Number of subjects: 559
Study 27531388 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial Direct Current Stimulation (tDCS) over the left dlPFC
Number of subjects: 19
Study 27531388 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial Direct Current Stimulation (tDCS)
Number of subjects: 19
Study 25733384 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 3982
Study 25733384 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 3982
Study 25733384 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 3982
Study 25733384 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 3982
Study 24090427 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS) training (47 minutes/day, 5 days/week) for 14 weeks
Number of subjects: 8
Study 24090427 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EMS training)
Number of subjects: 8
Study 21395680 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (5 mg/mL)
Number of subjects: 36
Study 21395680 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 36
Study 19147331 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP group (grafted autogenous bone + PRP)
Number of subjects: 30
Study 19147331 — intervention group
Group type: COMPARATOR
Intervention: non-PRP group (grafted autogenous bone alone)
Number of subjects: 30
Study 17457134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium parecoxib (1 mg/kg)
Number of subjects: 12
Study 17457134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15764246 — intervention group
Group type: EXPERIMENTAL
Intervention: TURBT+5'-DFUR (n = 47; initial 23 months)
Number of subjects: 112
Study 15764246 — intervention group
Group type: COMPARATOR
Intervention: TURBT alone (n = 65, final 23 months)
Number of subjects: 112
Study 15764246 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'-DFUR administration
Number of subjects: 112
Study 15764246 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'-DFUR
Number of subjects: 112
Study 12391352 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalamotomy
Number of subjects: 62
Study 12391352 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalamic stimulation
Number of subjects: 62
Study 10535230 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track intervention (multisite, multicomponent preventive intervention including classroom program, social skills training, academic tutoring, parent training, and home visiting)
Number of subjects: 0
Study 10535230 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track intervention
Number of subjects: 0
Study 7751425 — intervention group
Group type: EXPERIMENTAL
Intervention: IMDUR 60-mg tablets
Number of subjects: 18
Study 7751425 — intervention group
Group type: COMPARATOR
Intervention: 5-ISMN 60-mg solution
Number of subjects: 18
Study 7751425 — intervention group
Group type: EXPERIMENTAL
Intervention: IMDUR 60-mg tablets with food
Number of subjects: 18
Study 7751425 — intervention group
Group type: EXPERIMENTAL
Intervention: IMDUR 60-mg tablets under fasted conditions
Number of subjects: 18
Study 2215592 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh embryos transferred to recipients
Number of subjects: 40
Study 2215592 — intervention group
Group type: COMPARATOR
Intervention: Frozen and thawed embryos transferred to recipients
Number of subjects: 40
Study 342850 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 21
Study 342850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21